Objective: Posttraumatic epilepsy (PTE) is a significant complication following traumatic brain injury (TBI), yet the role of genetic variation in modulating PTE onset is unclear. We hypothesized that TBI-induced inflammation likely contributes to seizure development. We assessed whether genetic variation in the interleukin-1beta (IL-1b) gene, IL-1b levels in cerebrospinal fluid (CSF) and serum, and CSF/serum IL-1b ratios would predict PTE development post-TBI. Methods: We investigated PTE development in 256 Caucasian adults with moderateto-severe TBI. IL-1b tagging and functional single nucleotide polymorphisms (SNPs) were genotyped. Genetic variance and PTE development were assessed. Serum and CSF IL-1b levels were collected from a subset of subjects (n = 59) during the first week postinjury and evaluated for their associations with IL-1b gene variants, and also PTE. Temporally matched CSF/serum IL-1b ratios were also generated to reflect the relative contribution of serum IL-1b to CSF IL-1b. Results: Multivariate analysis showed that higher CSF/serum IL-1b ratios were associated with increased risk for PTE over time (p = 0.008). Multivariate analysis for rs1143634 revealed an association between the CT genotype and increased PTE risk over time (p = 0.005). The CT genotype group also had lower serum IL-1b levels (p = 0.014) and higher IL-1b CSF/serum ratios (p = 0.093). Significance: This is the first report implicating IL-1b gene variability in PTE risk and linking (1) IL-1b gene variation with serum IL-1b levels observed after TBI and (2) IL-1b ratios with PTE risk. Given these findings, we propose that genetic and IL-1b ratio associations with PTE may be attributable to biologic variability with blood-brain barrier integrity during TBI recovery. These results provide a rationale for further studies (1) validating the impact of genetic variability on IL-1b production after TBI, (2) assessing genetically mediated signaling mechanisms that contribute to IL-1b CSF/serum associations with PTE, and (3) evaluating targeted IL-1b therapies that reduce PTE.
Posttraumatic epilepsy (PTE) accounts for 20% of symptomatic seizures and 5% of all seizures in the general population. 1 For those with penetrating head injury, subdural hematoma (SDH), or depressed skull fracture, more than 20% develop PTE. 2 Time to first seizure varies greatly, with clinical onset reported >10 years postinjury. 3 PTE is associated with increased mortality, and death at a younger age, compared to patients without PTE. 4 Those with PTE also are at a significant disadvantage regarding physical, cognitive, and psychosocial issues that adversely affect outcome. 5 Despite evidence against effective PTE prevention treatments, 6 people with traumatic brain injury (TBI) frequently receive long-term anticonvulsant therapy, often resulting in unwanted side effects and regular monitoring. Thus, identifying reliable biomarkers for epileptogenesis and PTE risk prognostication could have broad clinical implications for TBI treatment and recovery.
Increasing evidence implicates glial cell activation and subsequent cytokine production following acute seizures as an important contributor to epileptogenesis. 7, 8 Of interest, a similar glial cell and cytokine response is also observed following TBI. One of the most widely studied biomarkers for epileptogenesis is interleukin-1beta (IL-1b), a proinflammatory cytokine produced in the central nervous system (CNS) by activated microglia and astrocytes, as well as in the periphery by macrophages and other immune cells. Following TBI, injured tissue increases extracellular adenosine triphosphate, which mediates CNS microglia activation 9 as well as IL-1b processing and release. 10 Previous studies have reported increased IL-1b expression, 11 microglial activation, 12 and cell death up to a year following TBI, 13 suggesting that IL-1b may be a useful marker of chronic inflammation that facilitates and perpetuates PTE risk.
Increased IL-1b production following TBI increases CNS hyperexcitability and excitotoxicity through Ca 2+ , glutamatergic, and GABAergic mechanisms potentially contributing to epileptogenesis. 14 Of interest, exogenous IL-1b administration increases seizure activity induced by various proconvulsant drugs in rodent models. 15 Furthermore, disruption of the IL-1b biosynthesis pathway, with IL-1b converting enzyme (ICE/caspase-1) inhibitors, results in delayed onset time and frequency of chemically induced seizures. 16 Studies investigating plasma and cerebrospinal fluid (CSF) IL-1b levels in populations with febrile seizures (FS) and temporal lobe epilepsy (TLE) have shown mixed results, 17 but do implicate IL-1b with the pathology. However, no studies have assessed IL-1b levels in association with the evolution of epileptogenesis and PTE risk following TBI.
Genetic variant associations with epilepsy are another viable biomarker path for predicting PTE development. Previous studies have identified multiple single nucleotide polymorphisms (SNPs) associated with increased seizure risk following TBI. 18, 19 The gene coding for IL-1b (IL-1B) is located in the 2q12-13 region on the long arm of chromosome 2. One commonly studied IL-1B SNP, rs16944, located at position À511 within the promoter region, reportedly increases susceptibility to common types of TLE. 20 Of interest, variation within this same SNP increases lipopolysaccharide (LPS)-induced IL-1b production two-to threefold. 21 Based on the known role of IL-1b in inflammation and risk for nontraumatic epilepsy, the goal of this study was to determine if genetic variability within the IL-1B gene and IL-1b biomarker profiles in CSF relative to serum in a TBI population were associated with PTE risk.
Methods

Study design and subjects
This study was approved by the at the University of Pittsburgh Institutional Review Board, using an IRBapproved consenting process. There were 354 subjects screened for this study at a single academic medical center as a part of a larger study evaluating genetics and biomarkers on outcomes for individuals with TBI. Based on allelic frequency information obtained from the database of Single Nucleotide Polymorphisms (dbSNP: http://www. ncbi.nlm.nih.gov/snp), this longitudinal retrospective cohort study was limited to Caucasians, and 32 subjects were excluded from the analysis. Subjects were 18-70 years old, had moderate to severe TBI (Glasgow Coma Scale [GCS] score ≤12), positive computed tomography (CT) scan confirming intracranial injury (TBI), and no history of premorbid seizures. Thirteen subjects had GCS >12, but were included in the moderate TBI category based on positive CT findings. Six subjects screened had premorbid seizures and were excluded. The remaining (n = 316) subjects who met the race, age, medical history, and injury criteria for inclusion were further screened based on our criteria for PTE analysis.
IL-1b genetics population
Time to first seizure was our primary variable of interest, and the cohort was further restricted to approximate the standard criteria for PTE. 22 PTE was defined as the time to first seizure occurring beyond the first week post-injury. Therefore, individuals who had their first seizure during the first week postinjury (n = 20) or died within the first week postinjury (n = 40) were excluded. Three deceased individuals had documented history of PTE prior to death and were included in the analysis. This final cohort consisted of n = 256 subjects. The time course for PTE development can vary based on mortality status and affect genetic relationships with PTE status and time to first seizure. In addition to Kaplan-Meier (KM) approaches for assessing time to first seizure, mortality status was handled in bivariate categorical analysis by removing subjects who died after the first week postinjury but did not seize, leaving n = 206 survivors. Time to mortality was handled in multivariate models using Cox regression (see statistical approach).
IL-1b level population
This group included subjects (n = 59) from the IL-1b genetics population that had ≥2 temporally matched cerebrospinal fluid (CSF) and serum samples available during the first week postinjury for IL-1b quantification (n = 143 for serum and CSF samples). Similar to the IL-1b genetics cohort, subjects who died after the first week but did not seize were removed, leaving (n = 46) survivors from which to analyze bivariate IL-1b associations with PTE. Time to mortality was adjusted in associated multivariate population analyses.
In addition, serum and CSF IL-1b levels for healthy adult control subjects were evaluated. CSF was obtained via lumbar puncture (n = 13), and serum was obtained by venipuncture (n = 11) from healthy control subjects. Control subjects were between 19 and 60 years old, with no past or current bleeding disorder, brain injury, or neurological disease. Women currently pregnant, or taking oral contraceptives or hormone replacement therapy, were excluded.
Critical care management of severe TBI Subjects evaluated were admitted to the neurotrauma intensive care unit over a 10-year period and treated in accordance with the Guidelines for the Management of Severe Head Injury. 23 Standard treatment included initial extraventricular drain placement, central venous, and arterial catheters. Surgical intervention for mass lesion decompression was performed when clinically necessary. Intermittent electroencephalography (EEG) was used to evaluate patients with clinical suspicion of epileptic activity. In accordance with previously published studies, patients with severe TBI were typically prescribed PTE prophylaxis for the first week postinjury. 24 
Demographics and injury data
Patient demographic variables, including age and sex were recorded. Medical records and University of Pittsburgh Medical Center (UPMC) trauma registry data were reviewed to abstract clinical information regarding GCS scores, injury mechanism, depressed skull fracture, subdural hematoma (SDH), injury severity score (ISS), isolated head injury status (IHI), and length of hospital stay. The highest GCS score in the first 24 h postinjury was recorded. Depressed skull fracture and/or SDH were identified based on radiographic reports. Information regarding antiepileptic drug (AEDs) use was recorded only if noted in the medical records as used for seizure prophylaxis or treatment.
ISS and IHI were determined based on the Abbreviated Injury Scale (AIS) scoring system, which determines severity of a specific injury based on the survivability of that injury. 25 The AIS categorizes injury to a body region from 1 to 6, with six representing the highest chance of an injury being lethal. ISS, a measure of global anatomical injury severity, is defined as the sum of squares of scores from the three most severely affected body regions. 26 IHI status was based on the head AIS score, with ≥3 being considered a severe TBI. All subjects had a head AIS ≥3. Isolated TBI (IHI) was defined as head AIS ≥3 in patients with AIS <3 for each of the three most injured extracranial body regions. Nonisolated TBI was defined as head AIS score ≥3, and an AIS score of ≥3 for at least one extracranial body region. 27 
Seizure assessment
Electronic medical records were reviewed for information about PTE, and time to first seizure. PTE determinations were abstracted from patient history and physical, ambulance, emergency room, and EEG reports as well as discharge/transfer summaries and inpatient/outpatient progress notes. Any mention of seizures, convulsions, or status epilepticus occurring after the first week postinjury was considered as evidence of PTE. PTE follow-up was censored to 3 years postinjury, since all subjects had complete ascertainment of PTE status during this period. There was no difference in EEG procurement between subjects included in this study and normal standard of care.
DNA extraction, SNP selection, and genotyping DNA was extracted from one of two sources for each subject, whole blood or CSF. Whole blood was collected into ethylenediaminetetraacetic acid (EDTA) Vacutainer tubes, processed to retrieve the buffy coat, and DNA was extracted using a simple salting-out procedure. 28 CSF was collected by passive drainage, and DNA was extracted from white blood cells using QIAamp DNA extraction protocol for extraction from body fluids (Qiagen Corporation Venlo, The Netherlands). Tagging SNPs rs1143633, rs1143634, and rs3136558 with a minor allele frequency of at least 20% were selected based on data from the HapMap database (International HapMap Project: http://hapmap.ncbi.nlm.nih. gov/) and SNP database (dbSNP: http://www.ncbi.nlm.nih. gov/projects/SNP). These tSNPs captured the variability of the gene, including 1,000 bases 5 0 upstream into the promoter region, based on data from build 36. Rs1143634 is also considered a functional SNP. Furthermore, functional SNPs rs1143627 and rs16944 were also selected for genotyping.
Genotyping was completed using TaqMan allele discrimination technology and commercially available 5 0 exonuclease Assay-on-Demand TaqMan assays (Applied Biosystems Incorporated Foster City, CA, U.S.A). Amplification and genotype assignments were conducted using the AB17000 and SDS 2.0 software (Applied Biosystems). Double-masked genotype assignments were made for each SNP, and each discrepancy was addressed using raw data or regenotyping. Hardy-Weinberg equilibrium was verified for all SNPs, indicating genotype distributions were within the expected proportions. Call rates for each SNP were >95%.
CSF and serum IL-1b collection and quantification
CSF samples were collected up to every 12 h for the first 6 days postinjury, and serum was collected daily. CSF samples were taken from an extraventricular drain (EVD) collection bag and blood samples via peripheral venipuncture. Collected samples were then centrifuged, aliquoted, and stored at À80°C until assay. A Luminex bead array assay (Milliplex Human High Sensitivity 9-plex; Millipore Billerica, MA, U.S.A) was used to measure IL-1b levels in CSF and serum. IL-1b levels were measured in available CSF and serum samples. Coefficients of variance for IL-1b assessments were <10%.
Statistical analysis
Statistical analyses were performed using SPSS version 20.0 (Chicago, IL, U.S.A.) and SAS (Cary, NC, U.S.A.). Summary statistics included means, medians, frequencies, and standard error of the mean (SEM). Independent t-test, or Mann-Whitney when appropriate, was used to assess differences between PTE groups and continuous variables. Chisquare analysis, using Fisher's exact test when appropriate, was used to assess differences between PTE and categorical variables, including IL-1b SNP genotypes.
To analyze serum and CSF IL-1b levels in the context of PTE, weekly averages were calculated based on daily IL-1b levels for the first week postinjury. Daily values >3 standard deviations above/below the population mean were considered outliers and excluded from analysis (CSF n = 8, serum n = 7 samples). Given the induction of both peripheral monocytes and CNS microglia to activated macrophages, we hypothesized that CSF IL-1b levels represented a mixture of CNS derived and peripherally generated IL-1b transported into the CSF. To express the relative contribution of serum IL-1b to measured CSF IL-1b levels, IL-1b ratios were calculated by dividing temporally matched CSF/serum samples, and daily ratios were then averaged in order to obtain a weekly IL-1b ratio. Significant bivariate associations (p < 0.05) were analyzed in multivariate models to determine genetic and other variable associations with cytokine ratios.
For those with PTE, Kaplan-Meier analysis was used to examine time to first seizure (8 days-3 years) by candidate SNP variation while adjusting for time to mortality. IL-1b ratios, and SNPs with genotypes that differed significantly in terms of PTE risk, were also examined using Cox proportional hazards models. Cox models were generated with time to first seizure (8 days-3 years) as the dependent variable and PTE incidence as the event of interest. Multivariate Cox models examined either IL-1b ratios or significant SNPs while adjusting for covariates significantly associated with PTE status identified in bivariate analysis. Cox models were also adjusted for GCS and depressed skull fracture given their documented relevance to TBI severity and PTE.
Results
Population description
IL-1b genetics population
There were 256 adults with moderate-to-severe TBI and genotype information that otherwise met the criteria for PTE analysis. Approximately 81.6% of the population were men and 18.4% women. Mean age AE standard error of the mean (SEM) was 35.0 AE 0.93 years. Median GCS score was 6, and mean acute care length of stay (LOS) was 22.5 AE 0.68 days. The most common mechanisms of injury included automobile accidents (50.4%), motorcycle accidents (20.3%), and falls (11.3%). Two hundred forty-nine individuals (97.3%) were given AEDs for seizure prophylaxis, and PTE developed in 42 individuals (16.4%). Of those patients with a diagnosis of PTE, 51.2% had at least one EEG obtained at the time of clinical presentation; 34.1% of PTE subjects had at least one EEG during acute care, whereas 70.7% of subjects had at least one EEG during the 1 week to 3 years postinjury surveillance period.
A breakdown of the population based on PTE status is provided in Table 1 . Individuals with a lower ISS score were more likely to develop PTE (p = 0.026). IHI status (p = 0.033) and SDH (p = 0.002) were also associated with PTE. Mortality was significantly associated with PTE, with those who died having lower PTE incidence. Thus, a mortality-adjusted PTE population was created (n = 206). There were no differences in injury or demographic information between the unadjusted and mortality adjusted PTE populations (data not shown).
IL-1b level population
There were 59 individuals with moderate to severe TBI and acute cytokine information to assess factors influencing IL-1b ratios and PTE (Table 1) . IHI status was associated with higher IL-1b ratios compared to those with more severe extracerebral injuries (p = 0.047). SDH was also associated with higher IL-1b ratios (p = 0.037). Lower serum IL-1b levels were associated with IHI status (p = 0.007) and SDH (p = 0.022). Higher ISS was associated with higher serum IL-1b levels (p = 0.006). IL-1b level and ratio (n = 46) comparisons to PTE among survivors showed no significant differences in injury or demographic information (data not shown).
Healthy control population
Members of the healthy control population were all Caucasian and were 61.5% male (n = 8). Mean age was 24.62 AE 11.16 years. Sensitivity analyses showed significant differences between TBI and control cohorts with regard to age and sex distributions. Given some reports of possible sex differences in inflammatory response after TBI, 29 we assessed whether there were differences by sex among controls and found no significant differences in serum (0.361 AE 0.230 women vs. 0.072 AE 0.036 men; p = 0.257), CSF (0.030 AE 0.005 women vs. 0.026 AE 0.003 men; p = 0.171), or ratio (0.400 AE 0.667 women vs. 0.441 AE 0.263 men; p = 0.257) IL-1b levels. Age was not significantly correlated with IL-1b serum, CSF, or ratio levels among controls (p = 0.686, 0.733, 0.788, respectively).
Acute IL-1b levels
Mean daily and mean weekly CSF and serum IL-1b levels among survivors were compared to healthy controls.
Mean daily and mean weekly CSF IL-1b levels for the TBI group were higher than controls (p ≤ 0.001 all comparisons) (Fig. 1A) . CSF/serum IL-1b ratios were higher on d3 postinjury (p = 0.025), and there was a trend toward higher weekly average levels (p = 0.070) compared to controls (Fig. 1B) . Serum IL-1b levels did not differ from controls (Fig. 1C ). There were no significant sex differences in serum Acute IL-1b levels and PTE development Among survivors, weekly IL-1b ratios were higher in those with PTE versus no-PTE (PTE = 3.794 AE 2.274; no-PTE = 0.8207 AE 0.1495; p = 0.020) (Fig. 2A) . Serum IL-1b was lower in the PTE group (PTE = 0.2007 AE 0.1290 pg/ml; no-PTE = 0.7239 AE 0.3501 pg/ml; p = 0.016) (Fig. 2B) . CSF IL-1b levels were not different between PTE groups (PTE = 0.1964 AE 0.0901; no-PTE = 0.0876 AE 0.0159; p = 0.864) (Fig. 2C) . A Cox model for the IL-1b level population described in Table 1 , and adjusted for time to mortality, ISS, GCS, SDH, and depressed skull fracture, showed that higher IL-1b ratios were also associated with increased PTE risk over time (hazard ratio = 1.341; confidence interval [CI] 1.081-1.665; p = 0.008) ( Table 3 , Fig. 3A) . A similar Cox model showed no association between serum IL-1b levels and PTE risk over time (data not shown). Table 2 depicts the overall allelic frequencies for each SNP as well as bivariate associations within a mortalityadjusted subset of the overall population. There were no significant bivariate associations with PTE for rs1143633, rs3136558, rs1143627, and rs16944, regardless of mortality adjustment. However, bivariate evaluation showed that rs1143634 was related to PTE risk. PTE occurred in 17.6% of individuals with a CC genotype, 47.7% of individuals with a CT genotype, and no individuals with a TT genotype (p = 0.008). Consistent with previous studies, 30 individuals with the TT genotype (n = 13) at rs1143634 comprised only a small percentage of the overall population. Grouped (hazard ratio = 2.845; CI 1.372-5.900; p = 0.005) ( Table 3 , Fig. 3B ).
rs1143634 S association with PTE development
rs1143634 Associations with IL-1b levels
There were no significant bivariate associations with IL1b ratios, serum, or CSF levels for rs1143633, rs1143627, rs3136558, and rs16944 among subjects in the mortality adjusted IL-1b level population. Serum IL-1b levels were significantly different (p = 0.014) and IL-1b ratios showed a trend (p = 0.093) based on rs1143634 genotype (Table 2) . Grouped genotype analysis revealed that CT heterozygotes had lower serum IL-1b levels compared homozygotes (CT mean = 0.1571 AE 0.0552 pg/ml; CC + TT mean = 0.9661 AE 0.5048 pg/ml; p = 0.009). Also, CT heterozygotes also tended to have higher IL-1b ratios compared to homozygotes (CT mean = 2.615 AE 1.583; CC + TT mean = 0.8251 AE 0.2094; p = 0.062). Rs3136558 also tended to be associated (p = 0.058) with serum IL-1b levels, but further analysis showed a high degree of linkage disequilibrium (LD) between rs3136558 and rs1143634 within our population (p ≤ 0.001).
Discussion
PTE is a significant complication following TBI that leads to increased disability and long-term AED treatment. Mechanisms underlying epileptogenesis and PTE are not well understood, and despite characterized clinical risk factors for PTE, not all patients possessing these risk factors go on to develop PTE. Genetic variability, and associated variation in biologic responses to TBI, may account for increased PTE incidence in certain individuals. The most recent Epilepsy Benchmark Research Progress Report lists IL-1b as one potential biomarker for epilepsy based on recently published findings. 31 Previous work in our lab has shown that daily levetiracetam, a widely prescribed AED, reduces regional brain tissue IL-1b expression after experimental TBI, potentially contributing to its antiseizure effects in TBI. 32 This observation, along with other data showing a link between IL-1b and nontraumatic epilepsy, 33 provide a rationale for studying IL-1b and PTE development.
IL-1b is produced in the CNS and periphery. In healthy individuals, CNS IL-1b levels are very low and beneficial to physiologic processes such as memory formation and sleep. 34 However, TBI is associated with increased IL-1b expression, 11 which can persist for months postinjury. 35, 36 Elevated IL-1b levels are associated with early neuronal death and excitotoxicity, 13, 14 suggesting the importance of IL-1b regulation during TBI recovery. Based on these findings, and the known proconvulsant effects of IL-1b, we hypothesized that early TBI-induced changes in IL-1b levels would be associated with PTE. Given that both blood-brain barrier (BBB) disruption and peripheral inflammation occurs with TBI, 37 and that CSF IL-1b levels are likely to be a product of both CNS and peripheral production, we also explored CSF/serum IL-1b ratios as a reflection of the relative contribution of serum IL-1b to CSF IL-1b levels. Although our data showed CSF IL-1b levels were elevated in our PTE subpopulation, compared to controls, no difference in average CSF IL-1b was observed between the PTE and no-PTE groups. Serum IL-1b levels did not differ from controls. However, serum IL-1b levels were significantly lower in the PTE versus no-PTE group, suggesting relative differences in serum IL-1b transit into the CNS between these two groups. Of interest, individuals with high CSF/serum IL-1b ratios during the first week postinjury had significantly higher PTE risk, suggesting that although absolute CSF IL-1b are elevated after TBI, the relative contribution of IL-1b from the periphery is the measurement most sensitive to eventual PTE development. This association is interesting and has implications for early screening, yet further work is needed to determine if/how the serum and ratio associations also reflect something about how a persistent peripheral inflammatory state, recently characterized over the first year in a clinical population with moderate-to-severe injury, 36 may contribute to epileptogenesis and PTE development over the longterm. Multivariate Cox models showed that only IL-1b ratios were significantly associated with PTE risk overtime, indicating CSF/serum ratios appear to increase the specificity of the contribution of peripheral inflammation to CNS pathology.
Of interest, type II IL-1 transporters have been implicated in one report with blood to brain IL-1b transport across the BBB using an in vitro approach involving cerebromicrovascular endothelial cells. 38 Although clinical TBI studies suggest that some cytokines follow a brain-to-blood transport gradient, 39 similar studies do not identify such a gradient for IL-1b transport. 40 Our results show high serum IL-1b concentrations, relative to CSF, in our cohort with IL-1b levels that are suggestive of a blood-to-brain gradient for IL-1b (Fig. 1) . In addition, higher CSF to serum IL-1b ratios among those with PTE also support this hypothesis of blood-to-brain IL-1b transport (Fig. 2) . This finding, taken with rs1143634 associations with serum levels and the ratio, also suggests genetic variation influencing IL-1b transport capacity into the CNS over time as a plausible biologic mechanism to explore further how IL-1b pathology influences PTE risk.
Further work is needed to establish why higher IL-1b ratios acutely post-TBI can predict PTE onset months to years after injury. An increased acute inflammatory response might predict a prolonged period of chronic (CNS and peripheral) inflammation and BBB dysfunction that contributes to epileptogenesis and PTE. Notably, serum cytokine levels are elevated for at least a year after moderate to severe TBI, 36 which may contribute to BBB dysfunction and ongoing CNS inflammation. IL-1b induces IL-1b messenger RNA (mRNA) production in several cell types, including activated microglia, resulting in a positive feedback system that may perpetuate CNS inflammation over time. 41 Of interest, clinical imaging studies suggest that microglial activation can persist for years after TBI and is associated with ongoing white matter degeneration. 12 Furthermore, studies showing progressive cell death up to a year post-TBI, 13 suggest increases in extracellular ATP associated with apoptosis may chronically activate inflammasomes necessary for IL-1b production. 10 Higher acute IL-1b CSF/serum ratios within the PTE group may indicate various long-term physiological changes, associated with chronic inflammation, which promote epileptogenesis. Intraventricular IL-1b infusion can activate both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system, decreasing peripheral cellular immune responses and resulting in suppressed macrophage IL-1b secretion. 42 Thus, individuals with PTE may have acute hyperactivation of this neuroimmunomodulation system resulting in the lower serum IL-1b levels as we report in this study. Studies have also shown that increases in IL-1b and/or decreases in IL-1 receptor antagonist (IL-1Ra) significantly alters the frequency, duration, and threshold of chemically induced seizures. 15 In addition, delayed seizure progression has been reported in kindling studies that blocks nerve growth factor (NGF). 43 It is notable that IL-1b upregulates NGF both in vitro and in vivo, 44, 45 and application of IL-1Ra in a TBI rat model suppresses NGF-mediated plasticity. 46 Further work is needed to discern which, if any, of these altered physiologic states are reflected by the IL-1b CSF/serum ratio.
IL-1b gene variant analysis showed a relationship between rs1143634 genotype, PTE, and serum IL-1b levels as well as the CSF/serum IL-1b ratio. Individuals with a CT genotype at rs1143634 had a significantly increased risk of PTE and those with the CT genotype had a significantly shorter time to first seizure (~5 months shorter on average), implicating variability at this locus in accelerating epileptogenesis. Although the minor allele frequency (MAF) for this SNP is 0.25, only 13 subjects were TT homozygotes. Of interest, none of these subjects developed PTE. So while this TT subgroup is small and potentially subject to sample bias, the data suggests that TT homozygotes are relatively protected against PTE and the CT heterozygotes are uniquely the "at risk" group. Furthermore, future validation studies would be unlikely to yield a dose-response association with PTE risk.
Heterozygote associations for genetic variation for genes coding membrane receptors can occur and may result in multiple actions that affect the phenotype of interest (e.g., differential effects of membrane trafficking for receptor protein heterodimers vs. homodimers). We have previously reported heterozygote associations with PTE for rs10920573 located on the ADORA1 gene. 19 Although not a membrane receptor, one might speculate an extracellular milieu with a mixture of different IL-1b isoforms theoretically may have a differential effect on target receptor binding, activation, or downstream signaling within inflammation pathways that leads to increased PTE risk. Given that heterozygosity at rs1143634 is also associated with decreased serum IL-1b, and that IL-1b can influence BBB permeability, it also stands to reason that IL-1b physiology-associated heterozygosity at rs1143634 may differentially facilitate serum IL-1b transport into the CSF compartment. Notably, IL-1b modulates expression and efflux functionality for BBB carrier transporters like ATPbinding cassette (ABC) transporters, 47 for which genetic variation may have differential effects on IL-1b levels 48 as well as other molecules like cortisol, 49 in the setting of TBI. It is notable that ABC transporters also facilitate IL-1b efflux from stimulated macrophages, 50 ,51 a function that may be particularly relevant in the context of IL-1b contributions from chronically activated microglia 12 to PTE development over time. Finally, significant widespread epigenetic modification is known to occur after TBI, 52 and given previous reports on how epigenetic changes within the IL-1b promoter can occur, 53 this may be another area for further study regarding mechanisms associated with increased PTE risk with rs1143634.
The rs1143634 SNP is located in a coding region on exon 5 of the IL1b gene; however, its functionality is still controversial. 54 Studies suggest that the T allele is associated with increased IL-1b production, 48 whereas others found no difference in IL-1b secretion. 55 Rs1143634 tags approximately a 1 kb region of the IL-1b gene, located on chromosome 2, that also contains missense SNPs rs141525736, rs139843362, and rs114640380 (HapMap phase 3; hapmap. org). However, these SNPs are not highly variable, and no literature exists regarding their functionality. In addition, it is unclear where LD decays for the region tagged by rs1143634, thus additional genotyping around the DNA block representing rs1143634 may be helpful to better understand the functional implications of variation, including heterozygosity, at this locus.
ISS, IHI, and SDH were all linked to PTE. Individuals with lower ISS, an IHI, or a subdural hematoma were more likely to develop PTE. Because ISS is a measure of global, anatomical injury severity, it is not surprising that individuals with an IHI also have lower ISS. However, ISS/IHI were not significant predictors of PTE in multivariate analysis. Our findings do support previous studies showing SDH can increase PTE risk. 2 Despite the promising findings linking IL-1b and PTE, some limitations should be considered. Medical record data abstraction makes it difficult to accurately assess recurrent seizures and PTE severity. As such, recurrent seizures were not tracked. In addition, subclinical or nonconvulsive seizures occurring in subjects still intubated and sedated beyond the first week postinjury may have been missed. The sample included only Caucasians with moderate-tosevere injury, thereby limiting the generalizability to persons with different racial backgrounds. Furthermore, the overall sample size is modest for a genetic association study. However, the cohort available for biomarker and genetic analysis used is one of the largest moderate-tosevere TBI cohorts currently available. Nonetheless, to our knowledge, this is the first research report implicating serum IL-1b contributions to CSF IL-1b levels and also genetic variability in the IL-1b gene with PTE. Further work is needed to replicate these findings in independent populations and to better understand the mechanistic implications associated with these relationships. If validated, the findings might stimulate further research testing agents that target IL-1b to prevent and treat PTE. If validated, the findings might also support future work assessing the utility of genetic screening paradigms, paired with EEG screening and clinical care pathways, which result in risk stratified treatment and prevention protocols for PTE. In addition, future work exploring genetic variation and levels for other biomarkers relevant to TBI-induced inflammation and PTE development is warranted.
